Skip to main
ESLA

ESLA Stock Forecast & Price Target

ESLA Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Estrella Immunopharma Inc is advancing its EB104 dual CD19/CD22 program, which aims to enhance treatment options for patients with B-cell malignancies and autoimmune diseases, potentially leading to strategic partnerships that could broaden the company's market presence. The recent progression into a higher dose cohort, bolstered by positive initial results showing a favorable safety profile and a complete response in one patient, positions Estrella favorably within the competitive T-cell therapy landscape. Furthermore, the innovative Artemis Technology platform offers a novel approach to CAR-T therapies, unlocking new opportunities in immunology and solid tumor treatments, a critical advancement in the biopharmaceutical sector.

Bears say

The financial data indicates a substantial increase in the market size for relapsed/refractory B-cell Non-Hodgkin's Lymphomas in China, which rose from approximately 21,946 to 613,609 over a series of time intervals. Despite this potential growth opportunity, Estrella Immunopharma may face challenges in capturing a significant market share, given the competitive landscape of biopharmaceuticals and the complexities involved in bringing CD19 and CD22-targeted therapies to market. Additionally, the reliance on advancements within a niche sector raises concerns about the firm's ability to sustain operational momentum and secure funding, contributing to a cautious outlook on the stock's performance.

ESLA has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Estrella Immunopharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Estrella Immunopharma Inc (ESLA) Forecast

Analysts have given ESLA a Strong Buy based on their latest research and market trends.

According to 1 analysts, ESLA has a Strong Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Estrella Immunopharma Inc (ESLA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.